Disc challenges in polycythemia vera, but Silence retains the lead on September 11, 2026 Disc Medicine DISC-3405 divesiran hepcidin Phase 2 trial Phase 3 development Polycythemia SANRECO Silence Therapeutics TMPRSS6 gene vera +
Gene‑silencing drug divesiran posts strong Phase 2 win in rare blood cancer on August 11, 2026 divesiran gene-silencing Hematocrit procedure Hematologic Neoplasms Hepcidin Infrequent Polycythemia RNA, Small Interfering rusfertide SANRECO Silence Therapeutics ' Takeda TMPRSS6 gene Venous blood sampling Vera +